1800-272-662
Shopping Cart 0
countryflagAU
Login

Arovella Therapeutics Ltd

Healthcare AU ALA

0.074AUD
-0.001(1.33%)

Last update at 2026-03-13T05:10:00Z

Day Range

0.070.07
LowHigh

52 Week Range

0.070.12
LowHigh

Fundamentals

  • Previous Close 0.07
  • Market Cap89.33M
  • Volume122465
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-8.36884M
  • Revenue TTM3.21M
  • Revenue Per Share TTM0.003
  • Gross Profit TTM 3.21M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -7.50917M -8.74603M -11.23011M -8.62059M -5.04746M
Minority interest - - - - -
Net income -7.50917M -8.74603M -10.18135M -8.62059M -5.04746M
Selling general administrative 3.06M 2.77M 3.10M 2.79M 2.17M
Selling and marketing expenses - 1.28M 0.43M - -
Gross profit 0.14M -0.02598M -2.99988M 0.09M 0.03M
Reconciled depreciation 0.11M 0.04M 0.84M 0.55M 0.65M
Ebit -11.20279M -10.67253M -9.68074M -7.59260M -3.75290M
Ebitda -11.09550M -10.62955M -8.84356M -7.04111M -3.10073M
Depreciation and amortization 0.11M 0.04M 0.84M 0.55M 0.65M
Non operating income net other - - - - -
Operating income -11.20279M -10.81126M -9.68074M -7.59260M -3.75290M
Other operating expenses 11.34M 10.83M 10.09M 7.89M 4.92M
Interest expense - 0.00863M 0.02M 0.19M 0.03M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.39M 0.14M 0.02M 0.19M 0.03M
Net interest income 0.39M 0.13M 0.00935M -0.19087M -0.02675M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -3.30326M -1.93512M -1.04876M 0.19M 0.94M
Total revenue 0.14M 0.02M 0.41M 0.30M 0.26M
Total operating expenses 11.34M 10.79M 6.68M 7.69M 4.70M
Cost of revenue - 0.04M 3.41M 0.21M 0.22M
Total other income expense net 3.69M 2.07M -1.54937M -0.83327M -0.35460M
Discontinued operations - - - - -
Net income from continuing ops -7.50917M -8.74603M -10.18135M -8.62059M -5.04746M
Net income applicable to common shares -7.50917M -8.74604M -10.18135M -8.62059M -5.04747M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 21.60M 13.28M 5.47M 9.21M 10.69M
Intangible assets - - 0.00000M 2.25M 2.91M
Earning assets - - - - -
Other current assets 0.19M 0.44M 0.20M 0.48M 0.09M
Total liab 1.52M 2.06M 1.69M 1.60M 1.71M
Total stockholder equity 20.08M 11.23M 3.78M 7.62M 8.98M
Deferred long term liab - - - 2.12M 2.78M
Other current liab - 0.92M 0.61M 0.69M 1.39M
Common stock - 104.30M 88.87M 83.54M 77.00M
Capital stock 120.13M - 88.87M 83.54M 77.00M
Retained earnings -102.83728M -95.50556M -87.05540M -77.02451M -68.47235M
Other liab - - 0.00922M 0.00930M 0.00791M
Good will - - - - -
Other assets - 0.00000M - 2.12M 2.78M
Cash 20.88M 12.71M 5.18M 6.07M 6.72M
Cash and equivalents - - 5.18M 6.07M 6.72M
Total current liabilities 1.49M 2.04M 1.68M 1.51M 1.69M
Current deferred revenue - 0.14M - 0.35M 1.19M
Net debt - -12.71441M - -5.92616M -6.63796M
Short term debt - - 0.00000M 0.07M 0.08M
Short long term debt - - - 0.00112M 0.00572M
Short long term debt total - - - 0.14M 0.08M
Other stockholder equity - - 1.96M 1.11M 0.45M
Property plant equipment - - 0.05M 0.37M 0.43M
Total current assets 21.17M 13.15M 5.42M 6.59M 7.34M
Long term investments - - - - -
Net tangible assets - - 3.78M 7.48M 8.85M
Short term investments - - - - -
Net receivables - - 0.01M 0.04M 0.53M
Long term debt - - - - 0.00274M
Inventory - - - - 0.00000M
Accounts payable 0.94M 0.98M 0.77M 0.75M 0.23M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 2.44M - 1.11M 0.45M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - -0.00000M - - -
Deferred long term asset charges - - - - -
Non current assets total 0.43M 0.13M 0.05M 2.62M 3.34M
Capital lease obligations - - - 0.14M 0.07M
Long term debt total - - 0.00000M 0.08M 0.00274M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -0.43211M -0.17934M 0.10M -0.56600M -0.51455M
Change to liabilities - - 0.22M -0.26969M -0.45324M
Total cashflows from investing activities -0.43211M -0.17934M 0.10M -0.56600M -0.51455M
Net borrowings - - -0.07182M -0.06820M -0.05758M
Total cash from financing activities 15.52M 14.61M 5.41M 6.19M 9.80M
Change to operating activities - - 0.26M -0.29876M -0.33944M
Net income -7.50917M -8.74603M -10.18135M -8.62059M -5.04746M
Change in cash 8.16M 7.54M -0.89563M -0.64623M 5.74M
Begin period cash flow 12.71M 5.18M 6.07M 6.72M 0.98M
End period cash flow 20.88M 12.71M 5.18M 6.07M 6.72M
Total cash from operating activities -6.92997M -6.91387M -6.39765M -6.26825M -3.54453M
Issuance of capital stock 16.81M 14.61M 5.48M 6.26M 9.86M
Depreciation - 0.04M 0.84M 0.55M 0.65M
Other cashflows from investing activities -0.01922M -0.05000M 0.10M -0.53097M -0.34845M
Dividends paid - - - - -
Change to inventory - - -0.00000M - -
Change to account receivables - -0.01024M 0.03M 0.50M 0.34M
Sale purchase of stock -1.28750M 14.61M 5.48M 6.26M 9.86M
Other cashflows from financing activities - -0.17934M -0.07182M -0.06820M -0.05758M
Change to netincome - - 2.44M 1.87M 1.31M
Capital expenditures 0.41M 0.13M 0.00272M 0.57M 0.51M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.37958M 0.64M 0.51M -0.07110M -0.45715M
Stock based compensation - 1.05M 0.87M 0.58M 0.04M
Other non cash items -6.55038M 0.10M 3.86M 2.75M 2.73M
Free cash flow -7.34286M -7.04321M -6.40037M -6.83424M -4.05908M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ALA
Arovella Therapeutics Ltd		 -0.001 1.33% 0.07 - - 27.83 4.79 645.36 -3.352
CSL
CSL Ltd		 -0.01 0.0071% 141.03 16.27 19.23 4.44 2.61 3.90 11.73
TLX
TELIX Pharmaceuticals Ltd		 0.06 0.53% 11.29 - 1111.11 4.73 6.52 3.77 86.30
MSB
Mesoblast Ltd		 -0.03 1.40% 2.11 - 454.55 41.58 3.42 30.11 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.19 1.59% 11.76 51.13 44.25 23.04 4.47 18.83 55.27

Reports Covered

Stock Research & News

View All

Profile

Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.

Arovella Therapeutics Ltd

Corporate One, Preston, VIC, Australia, 3072

Key Executives

Name Title Year Born
Dr. Michael Baker CEO, MD & Director NA
Mr. Phillip Hains B Bus, C.A., CA, M.B.A., MBA Company Sec. & CFO 1961
Mr. Stephen John Carter Consultant NA
Dr. Richard Franklin Project Director & Member of Scientific Advisory Board NA
Tony Macintyre GM & CTO NA
Dr. Nicole van der Weerden B.Sc., BSc (Hons), MBA (MBS), Ph.D. Chief Operating Officer NA
Mr. Tim Luscombe B.Com., C.A. Company Secretary & CFO NA
Michelle Long Administration Manager NA
Dr. Nicole van der Weerden B.Sc., BSc (Hons), MBA (MBS), Ph.D. Chief Operating Officer NA
Mr. Tim Luscombe B.Com., C.A. Company Secretary & CFO NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.